Cellestia Biotech picks up Series B
Cellestia Biotech AG, a clinical-stage biopharma company, has secured CHF 20 million in Series B funding.
Cellestia Biotech AG, a clinical-stage biopharma company, has secured CHF 20 million in Series B funding.
Copyright PEI Media
Not for publication, email or dissemination